Peter Grootenhuis (original) (raw)
Peter Grootenhuis (March 1960 – August 2019) was a Dutch-American Medicinal Chemist. Grootenhuis was the Project Leader and Co-Inventor of Ivacaftor (VX-770), the first CFTR potentiator FDA approved drug to treat the underlying cause of Cystic Fibrosis (CF) in patients with certain mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene (primarily the G551D mutation.), who account for 4-5% of CF cases. Grootenhuis also led the Vertex team to subsequent discovery of Orkambi, the combination of Ivacaftor and Lumacaftor(VX-809), approved to treat CF in people with two copies of the F508del mutation (~ 50% of CF patients). Most recently, Grootenhuis's team discovered Tezacaftor (VX-661) and Elexacaftor (VX-445), which in combination with Ivacaftor are the components of
| Property | Value |
|---|---|
| dbo:abstract | Peter Grootenhuis (March 1960 – August 2019) was a Dutch-American Medicinal Chemist. Grootenhuis was the Project Leader and Co-Inventor of Ivacaftor (VX-770), the first CFTR potentiator FDA approved drug to treat the underlying cause of Cystic Fibrosis (CF) in patients with certain mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene (primarily the G551D mutation.), who account for 4-5% of CF cases. Grootenhuis also led the Vertex team to subsequent discovery of Orkambi, the combination of Ivacaftor and Lumacaftor(VX-809), approved to treat CF in people with two copies of the F508del mutation (~ 50% of CF patients). Most recently, Grootenhuis's team discovered Tezacaftor (VX-661) and Elexacaftor (VX-445), which in combination with Ivacaftor are the components of Trikafta, a drug approved by the FDA in 2019 to treat CF in more than 90% of CF patients. For Grootenhuis’ contributions to the discovery of these compounds, he was awarded the 2018 IUPAC Richter Prize, the American Chemical Society’s 2013 Heroes of Chemistry Award, and inducted into the American Chemical Society Division of Medicinal Chemistry Hall of Fame. Grootenhuis has contributed to the discovery of over 11 clinical candidates, co-authored more than 100 peer reviewed papers and is inventor of 65 + U.S Patents, and more than 50 EU Patents. (en) |
| dbo:wikiPageID | 64609613 (xsd:integer) |
| dbo:wikiPageLength | 10644 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1122609501 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Royal_Netherlands_Chemical_Society dbr:San_Diego dbr:Peter_Kollman dbr:Cystic_fibrosis dbr:Cystic_fibrosis_transmembrane_conductance_regulator dbr:University_of_California,_San_Francisco dbr:University_of_Groningen dbr:University_of_Twente dbr:Utrecht_University dbr:Vertex_Pharmaceuticals dbc:1960_births dbr:Organic_chemistry dbr:Organon_International dbr:Okinawan_kobudō dbr:Elexacaftor dbr:Elexacaftor/tezacaftor/ivacaftor dbr:Lumacaftor/ivacaftor dbr:Bristol-Myers_Squibb dbc:21st-century_Dutch_chemists dbr:Vrije_Universiteit_Amsterdam dbr:American_Chemical_Society dbr:Dutch_Americans dbr:Food_and_Drug_Administration dbr:Harvard_University dbc:Cystic_fibrosis dbr:Ivacaftor dbc:2019_deaths dbc:20th-century_Dutch_chemists dbr:Chemistry dbr:Karate dbr:Black_belt_(martial_arts) dbr:Tezacaftor dbr:Martin_Karplus dbr:Okinawa dbr:Sensei dbr:Medicinal_chemistry dbr:DuPont_Pharmaceuticals dbr:Postdoctoral_fellowship dbr:Deltagen_Inc dbr:Deltagen_Pharmaceuticals dbr:IUPAC-Richter_Prize dbr:Noordwijkerhout-Camerino_Prize |
| dbp:wikiPageUsesTemplate | dbt:Authority_control dbt:Citation_needed dbt:Improve_categories dbt:Reflist dbt:Short_description dbt:Unreferenced_section |
| dct:subject | dbc:1960_births dbc:21st-century_Dutch_chemists dbc:Cystic_fibrosis dbc:2019_deaths dbc:20th-century_Dutch_chemists |
| rdf:type | owl:Thing |
| rdfs:comment | Peter Grootenhuis (March 1960 – August 2019) was a Dutch-American Medicinal Chemist. Grootenhuis was the Project Leader and Co-Inventor of Ivacaftor (VX-770), the first CFTR potentiator FDA approved drug to treat the underlying cause of Cystic Fibrosis (CF) in patients with certain mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene (primarily the G551D mutation.), who account for 4-5% of CF cases. Grootenhuis also led the Vertex team to subsequent discovery of Orkambi, the combination of Ivacaftor and Lumacaftor(VX-809), approved to treat CF in people with two copies of the F508del mutation (~ 50% of CF patients). Most recently, Grootenhuis's team discovered Tezacaftor (VX-661) and Elexacaftor (VX-445), which in combination with Ivacaftor are the components of (en) |
| rdfs:label | Peter Grootenhuis (en) |
| owl:sameAs | wikidata:Peter Grootenhuis https://global.dbpedia.org/id/FPquP |
| prov:wasDerivedFrom | wikipedia-en:Peter_Grootenhuis?oldid=1122609501&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Peter_Grootenhuis |
| is dbo:wikiPageRedirects of | dbr:Grootenhuis,_Peter |
| is dbo:wikiPageWikiLink of | dbr:Grootenhuis,_Peter |
| is foaf:primaryTopic of | wikipedia-en:Peter_Grootenhuis |